220 related articles for article (PubMed ID: 11605044)
1. Transient shrinkage of a uterine leiomyosarcoma treated with GnRH agonist for a presumed uterine leiomyoma: comparison of magnetic resonance imaging finding before and during GnRH agonist treatment.
Kawamura N; Iwanaga N; Hada S; Maeda K; Sumi T; Ishiko O; Ogita S
Oncol Rep; 2001; 8(6):1255-7. PubMed ID: 11605044
[TBL] [Abstract][Full Text] [Related]
2. Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment.
Kawamura N; Ito F; Ichimura T; Shibata S; Umesaki N; Ogita S
Fertil Steril; 1997 Oct; 68(4):632-6. PubMed ID: 9341601
[TBL] [Abstract][Full Text] [Related]
3. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid.
Loong EP; Wong FW
Fertil Steril; 1990 Sep; 54(3):530-1. PubMed ID: 2118862
[TBL] [Abstract][Full Text] [Related]
4. Unsuspected uterine leiomyosarcoma discovered during treatment with a gonadotropin-releasing hormone analogue: a case report and literature review.
Milman D; Zalel Y; Biran H; Open M; Caspi B; Hagay Z; Dgani R
Eur J Obstet Gynecol Reprod Biol; 1998 Feb; 76(2):237-40. PubMed ID: 9481582
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the shrinking rate of uterine leiomyoma nodules using needle biopsy specimens.
Kasai M; Ichimura T; Kawamura N; Sumikura T; Matsuda M; Asano C; Sumi T; Ishiko O
Fertil Steril; 2012 Aug; 98(2):440-3. PubMed ID: 22749217
[TBL] [Abstract][Full Text] [Related]
6. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
7. [Clinical usefulness of GnRH agonist therapy for premenopausal women with uterine leiomyoma].
Kurose T; Hando T; Shiota A
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Jan; 47(1):35-41. PubMed ID: 7844451
[TBL] [Abstract][Full Text] [Related]
8. Aborted leiomyosarcoma after treatment with leuprolide acetate.
Mesia AF; Williams FS; Yan Z; Mittal K
Obstet Gynecol; 1998 Oct; 92(4 Pt 2):664-6. PubMed ID: 9764655
[TBL] [Abstract][Full Text] [Related]
9. Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma.
Kadhel P; Smail M; Borja De Mozota D
J Gynecol Obstet Hum Reprod; 2017 Sep; 46(7):609-611. PubMed ID: 28647614
[TBL] [Abstract][Full Text] [Related]
10. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma.
Higashijima T; Kataoka A; Nishida T; Yakushiji M
Eur J Obstet Gynecol Reprod Biol; 1996 Sep; 68(1-2):169-73. PubMed ID: 8886702
[TBL] [Abstract][Full Text] [Related]
12. Prolapsed leiomyoma with severe haemorrhage after GnRH analogue therapy.
Kriplani A; Agarwal N; Parul D; Bhatla N; Saxena AK
J Obstet Gynaecol; 2002 Jul; 22(4):449-51. PubMed ID: 12521484
[No Abstract] [Full Text] [Related]
13. MRI of uterine leiomyosarcoma.
Pattani SJ; Kier R; Deal R; Luchansky E
Magn Reson Imaging; 1995; 13(2):331-3. PubMed ID: 7739376
[TBL] [Abstract][Full Text] [Related]
14. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.
Flierman PA; Oberyé JJ; van der Hulst VP; de Blok S
BJOG; 2005 May; 112(5):638-42. PubMed ID: 15842290
[TBL] [Abstract][Full Text] [Related]
15. [New possibilities for differentiated therapy of leiomyoma of the uterus using the GnRH agonist zoladex].
Gesenhues T; Hackenberg R; Diechert U; Duda V; Sturm G; Schulz KD
Geburtshilfe Frauenheilkd; 1989 Feb; 49 Suppl 1():96-8. PubMed ID: 2522904
[TBL] [Abstract][Full Text] [Related]
16. Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience.
Okuda S; Oshio K; Shinmoto H; Tanimoto A; Asada H; Fujii T; Yoshimura Y; Kuribayashi S
Radiology; 2008 Sep; 248(3):917-24. PubMed ID: 18710984
[TBL] [Abstract][Full Text] [Related]
17. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
18. Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin.
Ueki M; Okamoto Y; Tsurunaga T; Seiki Y; Ueda M; Sugimoto O
J Obstet Gynaecol (Tokyo 1995); 1995 Feb; 21(1):1-7. PubMed ID: 8591104
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
20. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin.
Crow J; Gardner RL; McSweeney G; Shaw RW
Int J Gynecol Pathol; 1995 Jul; 14(3):235-42. PubMed ID: 8600075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
